公开(公告)号：US20250129050A1

公开(公告)日：2025-04-24

申请号：US18832887

申请日：2023-01-26

Applicant: Amgen Inc.

Inventor： Sebastien CAILLE ,  Daniel Gerard GREENE ,  Michael Thomas CORBETT ,  Carolyn WEI

IPC: C07D401/14 ,  C07D221/20 ,  C07F3/00

Abstract: The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).

公开(公告)号：US20230192682A1

公开(公告)日：2023-06-22

申请号：US17776950

申请日：2020-11-13

Applicant: AMGEN INC.

Inventor： Michael Thomas CORBETT ,  Sebastien CAILLE

IPC: C07D471/04 ,  C07D213/73

CPC classification number: C07D471/04 ,  C07D213/73

Abstract: The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.